
SARS-CoV-2 Spike 265-279, YYVGYLQPRTFLLKY
Description
About SARS-CoV-2 Spike 265-279, YYVGYLQPRTFLLKY
The SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2) Spike glycoprotein Peptide (IEDB: 1314078) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Spike glycoprotein Peptide, H-YYVGYLQPRTFLLKY-OH (Uniprot: P0DTC2 aa: 265-279) from JPT is produced under strict quality control and quality management.
SARS-CoV-2 Spike 265-279, YYVGYLQPRTFLLKY - Specifications
- Peptide sequence: H-YYVGYLQPRTFLLKY-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Covid-19
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for SARS-CoV-2 Spike 265-279, YYVGYLQPRTFLLKY
References:
Read References with JPT’s Antigen Peptides
SARS-CoV-2 Spike 265-279, YYVGYLQPRTFLLKY has been described in:
SARS-CoV-2 specific T-cells Are Rapidly Expanded for Therapeutic Use and Target Conserved Regions of Membrane Protein., Blood, 2020 (PMID: 33104167)
Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein., Emerg Microbes Infect, 2022 (PMID: 35171086)
Documentation
Documentation for SARS-CoV-2 Spike 265-279, YYVGYLQPRTFLLKY
Properties
Properties of SARS-CoV-2 Spike 265-279, YYVGYLQPRTFLLKY
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Covid-19 |
Layout: | Freeze-dried in glass vial |
Organism: | SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2) |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to SARS-CoV-2 Spike 265-279, YYVGYLQPRTFLLKY
Information | Values |
---|---|
Sequence: | H-YYVGYLQPRTFLLKY-OH |
Specifications: | 15mer peptide as TFA salt |